A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray

Trial Profile

A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs B 244 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions
  • Sponsors AOBiome
  • Most Recent Events

    • 13 Apr 2017 Results published in an AOBiome media release.
    • 13 Apr 2016 Status changed from recruiting to completed.
    • 25 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top